天使症候群（AS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2035 年，義大利的天使症候群市場規模將從約 2,800 萬美元成長到 1.95 億美元。
• 市場成長受以下因素支撐：
• 基因標靶治療的研發正在取得進展。
• 診斷技術和患者識別方面的改進
• 市場擴張預計將由罕見疾病的高附加價值治療方案推動。
• 未來的成長取決於疾病修正治療和基因替代療法的商業化是否成功。

天使症候群（AS）概述

天使症候群是一種神經遺傳性疾病，由母系UBE3A基因表現缺失引起，導致泛素依賴性蛋白水解和突觸功能受損。此病表現為嚴重的智慧障礙、語言發展遲緩、共濟失調、癲癇發作以及典型的開朗性格。診斷需結合甲基化分析、UBE3A基因定序及染色體微陣列分析。癲癇發作頻率和功能障礙程度反映了疾病的嚴重程度。癲癇治療包括丙戊酸、左乙拉西坦和大麻二酚。大麻二酚對難治性肌陣攣性癲癇發作有效，但其對認知功能的鎮靜作用有限。標靶UBE3A反義轉錄本以恢復父系基因表現的反義寡核苷酸（ASO）療法目前正處於臨床試驗的最後階段。定期進行神經發育監測、支持性溝通和以家庭為中心的支持，對於終身管理生活品質至關重要。

主要亮點

• 據預測，德國的天使症候群病例總數將從 2025 年的約 6,772 例增加到 2035 年的 6,896 例。
• 天使症候群是一種罕見的遺傳性神經發育障礙，其特徵是嚴重的認知和運動障礙。
• 患者會出現發育遲緩、言語障礙、癲癇發作和行為異常。
• 由於可用於緩解疾病的治療選擇有限，因此仍有很大的未滿足需求。
• 新型基因療法和標靶神經系統治療方法正在改變醫療保健的未來。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Ionis Pharmaceuticals, Inc.
• Ultragenyx Pharmaceutical Inc.
• MavriX Bio, LLC
• Neuren Pharmaceuticals Limited
• Hoffmann-La Roche
• Healx AI

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Angelman Syndrome (AS) Market Outlook

Thelansis's "Angelman Syndrome (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Angelman Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Angelman Syndrome (AS) Overview

Angelman Syndrome is a neurogenetic disorder caused by loss of maternal UBE3A expression, impairing ubiquitin-mediated protein degradation and synaptic function. It presents with severe intellectual disability, absent speech, ataxic gait, seizures, and a characteristically happy demeanor. Diagnosis combines methylation analysis, UBE3A sequencing, and chromosomal microarray; seizure burden and functional impairment reflect severity. Seizure management incorporates valproate, levetiracetam, and cannabidiol, the latter offering efficacy in refractory myoclonic episodes with limited cognitive sedation. ASO therapies targeting UBE3A antisense transcripts to restore paternal gene expression are in advanced clinical trials. Regular neurodevelopmental monitoring, augmentative communication, and family-centred support underpin lifelong quality-of-life management.

Key Highlights

• In Germany, total prevalent Angelman syndrome cases are projected to increase from approximately 6,772 in 2025 to 6,896 by 2035.
• Angelman syndrome remains a rare genetic neurodevelopmental disorder associated with severe cognitive and motor impairment.
• Patients experience developmental delays, speech impairment, seizures, and behavioral abnormalities.
• Significant unmet need persists due to limited disease-modifying treatment options.
• Emerging gene therapies and targeted neurological treatments are transforming the future treatment landscape.

Market Overview

• The Italy Angelman syndrome market is projected to grow from approximately $28 MN to $195 MN by 2035.
• Market growth is supported by:
• Increasing development of gene-targeted therapies
• Improved diagnosis and patient identification
• Market expansion is expected to be driven by high-value rare disease treatments.
• Future growth will depend on successful commercialization of disease-modifying and gene replacement therapies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Ionis Pharmaceuticals, Inc.
• Ultragenyx Pharmaceutical Inc.
• MavriX Bio, LLC
• Neuren Pharmaceuticals Limited
• Hoffmann-La Roche
• Healx AI

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)